Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Medical Case Reports
Published in: Journal of Medical Case Reports 1/2022

Open Access 01-12-2022 | Cannabinoid | Case report

Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report

Authors: Ana Carolina Ruver-Martins, Maíra Assunção Bicca, Fabiano Soares de Araujo, Beatriz Helena Lameiro de Noronha Sales Maia, Fabrício Alano Pamplona, Elton Gomes da Silva, Francisney Pinto Nascimento

Published in: Journal of Medical Case Reports | Issue 1/2022

Login to get access

Abstract

Background

Cannabinoid-based therapy has been shown to be promising and is emerging as crucial for the treatment of cognitive deficits, mental illnesses, and many diseases considered incurable. There is a need to find an appropriate therapy for Alzheimer’s disease, and cannabinoid-based therapy appears to be a feasible possibility.

Case presentation

This report addresses the beneficial effect of cannabinoids in microdoses on improving memory and brain functions of a patient with mild-stage Alzheimer’s disease. The patient is a 75-year-old white man presenting with main symptoms of memory deficit, spatial and temporal disorientation, and limited daily activity. The experimental therapeutic intervention was carried out for 22 months with microdoses of a cannabis extract containing cannabinoids. Clinical evaluations using Mini-Mental State Examination and Alzheimer’s Disease Assessment Scale-Cognitive Subscale were performed.

Conclusions

Here we provide original evidence that cannabinoid microdosing could be effective as an Alzheimer’s disease treatment while preventing major side effects. This is an important step toward dissociating cannabinoids’ health-improving effects from potential narcotic-related limitations.
Literature
1.
Alzheimer’s Association. Alzheimer’s Disease: facts and figures. Alzheimers Dement. 2018;14(3):367–429.
2.
Pinto RS, et al. Doença de Alzheimer: Abordagem farmacoterapêutica. Bol Inf Geum. 2015;6(1):16–25.
3.
4.
Cline EN, et al. The amyloid-β oligomer hypothesis: beginning of the third decade. J Alzheimer’s Dis. 2018;64(s1):S567-610.CrossRef
5.
Iuvone T, et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134–41.PubMedCrossRef
6.
Westlake TM, et al. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience. 1994;63(3):637–52.PubMedCrossRef
7.
Núñez E, et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse. 2004;53(4):208–13.PubMedCrossRef
8.
Russo EB. Cannabis therapeutics and the future of neurology. Front Integr Neurosci. 2018;12:1–11.CrossRef
9.
Ronan PJ et al. Molecular mechanisms of cannabis signaling in the brain. In: Progress in molecular biology and translational science. United States: Elsevier Inc.; 2016. p. 123–47.
10.
Bilkei-Gorzo A, et al. A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat Med. 2017;23(6):782–7.PubMedCrossRef
11.
Abramovici H. Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. Canada: Health Canada; 2013. 152 p.
12.
13.
Martínez-Pinilla E, et al. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front Pharmacol. 2017;8(Oct):1–10.
14.
Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234–46.PubMedCrossRef
15.
Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.PubMedCrossRef
16.
Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriat Psychiatry. 2008;23(1):116.CrossRef
17.
Kuharic DB et al. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2021(9).
18.
Marcu J, Swisher D. Cannabis Inflorescence (Cannabis spp.). In: Upton R, Craker L, ElSohly M, Romm A, Russo E, Sexton M, editors. American herbal pharmacopoeia. Canada: American Herbal Pharmacopoeia; 2013. p. 1–64.
19.
Bertolucci PHF, et al. O mini-exame do estado mental em uma população geral: impacto da escolaridade. Arq Neuropsiquiatr. 1994;52(1):01–7.CrossRef
20.
Rosen WG, et al. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141(11):1356–64.PubMedCrossRef
21.
Keating GM. Delta-9-tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex®): a review in multiple sclerosis-related spasticity. Drugs. 2017;77(5):563–74.PubMedCrossRef
22.
Childs E, Lutz JA, De Wit H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug Alcohol Depend. 2017;177:136–44.PubMedPubMedCentralCrossRef
23.
Rey AA, et al. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA B receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology. 2012;37(12):2624–34.PubMedPubMedCentralCrossRef
24.
Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005;81(2):331–42.PubMedCrossRef
25.
26.
27.
Matsunaga S, et al. The efficacy and safety of memantine for the treatment of Alzheimer’s disease. Expert Opin Drug Saf. 2018;17(10):1053–61.PubMedCrossRef
28.
Van Den Elsen GAH, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84(23):2338–46.PubMedPubMedCentralCrossRef
29.
Herrmann N, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease. Am J Geriatr Psychiatry. 2019;27(11):1161–73.PubMedCrossRef
30.
Guy GW, Stott CG. The development of Sativex®—a natural cannabis-based medicine. Cannabinoids as Therapeutics. 2005;231–63.
31.
Liu CS, et al. Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease. CNS Drugs. 2015;29(8):615–23.PubMedCrossRef
32.
33.
34.
Martín-Moreno AM, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012;9:1–15.CrossRef
35.
Cao C, et al. The potential therapeutic effects of THC on Alzheimer’s disease. J Alzheimer’s Dis. 2014;42(3):973–84.CrossRef
36.
Bilkei-Gorzo A. The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc B Biol Sci. 2012;367:3326–41.CrossRef
37.
38.
39.
Dinh TP, et al. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids. 2002;121(1–2):149–58.PubMedCrossRef
40.
Ramírez BG, et al. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005;25(8):1904–13.PubMedPubMedCentralCrossRef
41.
Aso E, et al. Cannabinoid receptor 2 participates in amyloid-β processing in a mouse model of Alzheimer’s disease but plays a minor role in the therapeutic properties of a cannabis-based medicine. J Alzheimer’s Dis. 2016;51(2):489–500.CrossRef
42.
Aso E, et al. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J Alzheimer’s Dis. 2013;35(4):847–58.CrossRef
43.
Aso E, et al. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J Alzheimer’s Dis. 2015;43(3):977–91.CrossRef
44.
Fernández-Ruiz J, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013;75(2):323–33.PubMedCrossRef
45.
Suliman NA, et al. Delta-9-tetrahydrocannabinol (∆9-THC) induce neurogenesis and improve cognitive performances of male Sprague Dawley rats. Neurotox Res. 2018;33(2):402–11.PubMedCrossRef
Metadata
Title
Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report
Authors
Ana Carolina Ruver-Martins
Maíra Assunção Bicca
Fabiano Soares de Araujo
Beatriz Helena Lameiro de Noronha Sales Maia
Fabrício Alano Pamplona
Elton Gomes da Silva
Francisney Pinto Nascimento
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2022
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-022-03457-w

Other articles of this Issue 1/2022

Journal of Medical Case Reports 1/2022 Go to the issue

Case report

Acute myeloid leukemia causing acute thrombosis of the coronary arteries: a case report

Case report

Prenatal diagnosis of fetal midgut volvulus: a case report

Case report

Hemiballismus–hemichorea syndrome in an acute rehabilitation setting: two case reports 

Case report

Neonatal tetanus with good outcomes at a regional referral hospital in Eastern Uganda: a case report

Case report

Primary retroperitoneal hydatid cyst with intraperitoneal rupture: a case report

Case report

Adenosquamous carcinoma of the pancreas: two case reports and review of the literature